Author

Bei Zhao

University of Freiburg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:metagenomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Bodo GrimbacheriD· 2 shared Pavla Mrovecova· 2 shared Angelika Hofmann· 1 shared Bernd KammereriD· 1 shared Christoph SchelliD· 1 shared Jakob BeguniD· 1 shared Katja Gräwe· 1 shared Kun D. HuangiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Bodo GrimbacherORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The microbiome determines the phenotype in CTLA-4 insufficient mice and men

Bei Zhao, Lara Stopp, Pavaret Sivapornnukul, Simon Lagies, Kun D. Huang, Till Robin Lesker, Virginia Andreani, Rabina Giri, Pavla Mrovecova, Wiebke Schifferdecker, Angelika Hofmann, Katja Gräwe, Luis Braun, Jakob Begun, Christoph Schell, , Bodo Grimbacher

This study shows that the microbiome influences disease severity in CTLA-4 insufficient mice and humans by altering immune responses and promoting inflammation.

bioRxiv · Aug 21, 2026 · PreprintImmunology

Longitudinal Gut Microbiome Dynamics in Human CTLA-4 pathway Deficiencies: A One-Year Interventional Metagenomic Study

Máté Krausz, Bei Zhao, Pavla Mrovecova, Michele Proietti, Bodo Grimbacher

This study tracks gut microbiome changes in patients with CTLA-4 pathway deficiencies over one year of abatacept treatment, showing microbiome restructuring linked to disease improvement.

bioRxiv · May 22, 2026 · PreprintImmunology